Kimball Electronics Focuses on Medical
Kimball Electronics (NASDAQ:KE) reported fiscal fourth quarter 2025 results via press release on August 12, 2025, with net sales of $380.5 million (a 12% year-over-year decrease) and adjusted net income of $8.4 million ($0.34 per diluted share). Management highlighted aggressive medical contract manufacturing (CMO) expansion and a significantly reduced debt load, but guided for 2%-9% lower FY2026 revenue amid a major automotive program loss and targeted investment for future higher-margin opportunities.
Medical segment net sales reached $107 million, marking 5% year-over-year growth in Medical segment sales (non-GAAP) and comprising 28% of total sales; the segment benefitted from the restart and expansion of a major customer’s program (non-GAAP), with Kimball now moving from partial production to exclusive, company-wide final assembly. The new Indianapolis medical facility, a 300,000-square-foot site, is designed to accommodate several hundred million dollars of annual revenue, with initial capital spending of approximately $30 million in FY2026 and overall capital expenditures guided at $50 million to $60 million for FY2026.
This explicitly signals a structural pivot toward higher-value, less commoditized business.
Source Fool.com
